Thrombosis pp 227-241 | Cite as

Cardiac Thromboembolism: Evidence for Role of Platelets and Value of Platelet Suppressant Therapy

  • Edward Genton
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 102)


Thromboembolism remains a frequent and serious problem in cardiac patients. Methods to identify the thrombosis prone patient and the identification of safe and effective forms of treatment would be of great value.

The accumulating evidence which indicates that abnormalities in platelet tests are often present in cardiac patients and may help identify those at greatest risk of thrombosis is encouraging. It suggests that patients with cardiac disease are desirable groups for investigation. It also indicates that the platelet survival test may be useful as a reference against which new and more practical tests can be compared, as well as a means to identify useful platelet suppressant drugs or to monitor the effects of these drugs.


Oral Anticoagulant Prosthetic Valve Rheumatic Heart Disease Prosthetic Heart Valve Mitral Valve Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Genton E, Steele PP: Platelets, drugs and heart disease. In PLATELETS, DRUGS AND THROMBOSIS, edited by Hirsh J, Cade J, Gallus A, Schonbaum E. Basel, Karger, 1975.Google Scholar
  2. 2.
    Steele PP, Weily HS, Davies H, Genton E: Platelet function studies in coronary artery disease. CIRCULATION 48: 1194–1200, 1973.PubMedCrossRefGoogle Scholar
  3. 3.
    Ritchie JL, Harker LA: Platelet and fibrinogen survival in coronary atherosclerosis. AM J CARDIOL 39: 595–598, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Steele PP, Battock D, Pappas G, Genton E: Correlation of platelet survival time with occlusion of saphenous vein aortocoronary bypass grafts. CIRCULATION 53: 685–687, 1976.PubMedCrossRefGoogle Scholar
  5. 5.
    Genton E, Steele PP: Platelet survival: Value for the diagnosis of thromboembolism and evaluation of antithrombotic drugs. PROCEEDINGS OF INT’L. SYMPOSIUM ON PLATELETS AND THROMBOSIS, Milan, 1976. (In Press)Google Scholar
  6. 6.
    Genton E, Gent M, Hirsh J, Harker LA: Platelet-inhibiting drugs in the prevention of clinical thrombotic disease. N ENGL J MED 293:1174–1178, 1236–1240 and 1296–1300, 1975.Google Scholar
  7. 7.
    Research Committee of the Scottish Society of Physicians: Ischaemic heart disease: A secondary prevention trial using clofibrate. BR MED J 4: 775–784, 1971.CrossRefGoogle Scholar
  8. 8.
    Group of Physicians of the Newcastle upon Tyne Region: Trial of clofibrate in the treatment of ischaemic heart disease. BR MED J 4:767–775, 1971.Google Scholar
  9. 9.
    Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381, 1975.CrossRefGoogle Scholar
  10. 10.
    Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R: A randomized controlled trial of acetyl salicyclic acid in the secondary prevention of mortality from myocardial infarction. BR MED J 1: 436–440, 1974.PubMedCrossRefGoogle Scholar
  11. 11.
    Coronary Drug Project Research Group: Aspirin in coronary heart disease. J CHRONIC DIS 29: 625–642, 1976.CrossRefGoogle Scholar
  12. 12.
    Breddin K, Uberla K, Walter E: German-Austrian multicenter two-year prospective study on the prevention of secondary myocardial infarction by ASA in comparison to phenprocoumon and placebo. THROMB HAEMOSTAS 38: 168, 1977 (Abstract).Google Scholar
  13. 13.
    McEnany MT, DeSanctis RW, Harthorne JW, Mundth ED, Weintraub RM, Austen WG, Salzman EW: Effect of antithrombotic therapy on aortocoronary vein graft patency rates. CIRCULATION 54 (Suppl II): 2–124, 1976 (Abstract).Google Scholar
  14. 14.
    Weily H, Steele PP, Davies H, Pappas H, Genton E: Platelet survival in patients with substitute heart valves. N ENGL J MED 290: 534–537, 1974.PubMedCrossRefGoogle Scholar
  15. 15.
    Steele PP, Weily HS, Davies H, Genton E: Platelet survival in patients with rheumatic heart disease. N ENGL J MED 290: 537–539, 1974.PubMedCrossRefGoogle Scholar
  16. 16.
    Sullivan JM, Harken DE, Gorlin R: Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N ENGLJ MED 284: 1391–1394, 1971.CrossRefGoogle Scholar
  17. 17.
    Arrants JE, Hairston P: Use of Persantine in preventing thromboembolism following valve replacement. AM SURG 38: 432–435, 1972.PubMedGoogle Scholar
  18. 18.
    Taguchi K, Matsumura H, Washizu T, et al.: Effect of athrombogenic therapy, especially high dose therapy of dipyridamole, after prosthetic valve replacement. J CARDIOVASC SURG 16: 8–15, 1975.Google Scholar
  19. 19.
    Altman R, Boullon F, Rouvier J, Raca R, Fuente L, Favaloro R: Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J THORAC CARDIOVASC SURG 72: 127–129, 1976.PubMedGoogle Scholar
  20. 20.
    Dale J, Myhre E, Storstein O, Stormorken H, Efskind L: Prevention of arterial thromboembolism with acetylsalicyclic acid. AM HEART J 94: 101–111, 1977.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1978

Authors and Affiliations

  • Edward Genton
    • 1
  1. 1.McMaster UniversityHamiltonCanada

Personalised recommendations